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ABSTRACT
Familial hypercholesterolemia (FH) results from defective
low-density lipoprotein receptor (LDLR) activity, mainly
due to LDLR gene defects. Of the many different LDLR
mutations found in patients with FH, about 6% of single
base substitutions are located near or within introns, and
are predicted to result in exon skipping, retention of an
intron, or activation of cryptic sites during mRNA splicing.
This paper reports on the Portuguese FH Study, which
found 10 such mutations, 6 of them novel. For the
mutations that have not been described before or those
whose effect on function have not been analysed, their
effect on splicing was investigated, using reverse
transcriptase PCR analysis of LDLR mRNA from freshly
isolated blood mononuclear cells. Two of these variants
(c.313+6 TRC, c.2389GRT (p.V776L)) caused exon
skipping, and one caused retention of an intron
(c.135925CRG), whereas two others (c.2140+5 GRA
and c.106128TRC) had no apparent effect. Any effect
of c.1185GRC (p.V374V) on splicing could not be
determined because it was on an allele with a promoter
mutation (242CRG) that was probably not transcribed.
Variants in four patients lost to follow-up could not be
tested experimentally, but they almost certainly affect
splicing because they disrupt the invariant AG or GT in
acceptor (c.81822ARG) or donor (c.1060+1GRA,
c.1845+1delG and c.2547+1GRA) spice sites. These
findings emphasise that care must be taken before
reporting the presence or absence of a splice-site
mutation in the LDLR gene for diagnostic purposes. The
study also shows that relatively simple, quick and
inexpensive RNA assays can evaluate putative splicing
mutations that are not always predictable by available
software, thereby reducing genetic misdiagnosis of
patients with FH.
Familial hypercholesterolemia (FH) is a common
autosomal dominant disorder with a frequency of
about 1 in 500 in most European populations.
Patients diagnosed with FH characteristically have
high levels of low-density lipoprotein cholesterol
(LDLc) from birth, present with tendon xantho-
mata, and have an increased risk of premature
atherosclerosis and coronary heart disease (CHD).
FH results from defective low-density lipoprotein
receptor (LDLR) activity, caused mainly by muta-
tions in the LDL receptor gene (LDLR) itself.1
Many different types of mutations in LDLR have
been found in patients with FH. These range from
large deletions and rearrangements that disrupt
gene structure to single base substitutions that
compromise the structure or function of the
protein by introducing a premature termination
codon or a single amino acid substitution.
However, a significant proportion (approx 6%) of
the single base substitutions observed in patients
with FH do not affect the protein coding sequence.
These variants are often located in the 59 splice-
donor site or the 39 splice-acceptor site of an intron,
and are predicted to result in either exon skipping
or retention of an intron in the mRNA, although
this has not always been confirmed experimen-
tally. Other intronic variants may lie outside the
consensus splice-site sequence, but affect the
splicing branch point2 or create an alternative
splice site that is used preferentially.3 Alternative
splice sites can also arise as a result of a single base
substitution in the coding sequence.4
Although some splice-site mutations are easily
identified, based on a priori knowledge of their
location in the gene and their likely effect on the
consensus sequences for splice sites, others are
more difficult to predict. Consequently, software
packages have been developed that provide a
‘‘splice score’’ for a known or potential splice site,
based on the consensus sequences for natural splice
sites, and thereby indicate whether a particular
nucleotide substitution is likely to influence spli-
cing.5–7 However, several of the known natural
splice sites in the LDLR gene have relatively low
scores, so predictions are not always safe, and only
analysis of mRNA from the patient’s cells can
confirm that splicing is affected. To date, this has
been performed for only a few splicing alterations,
probably because of the perceived need to establish
stable cell lines from the patient to allow analysis
of LDLR mRNA.3 4 8
This paper reports on the Portuguese FH Study,
which was implemented to perform molecular
characterisation of patients with a clinical diag-
nosis of FH as an aid to diagnosis and identification
of index cases and affected relatives.9 In total, 10
potential splicing mutations were found, 6 of
which had either not been described previously or
for which their effect on function had not been
analysed.10 The aim of this study was to determine
whether these variants were mutations that
affected splicing of the LDLR mRNA. For this,
LDLR mRNA from freshly isolated blood mono-
nuclear cells from patients with FH was analysed
by reverse transcriptase (RT)-PCR.
METHODS
Patient recruitment
Samples of whole blood (10 ml for children and
15 ml for adults) were taken from index patients
with a potential splice-site mutation in LDLR
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found during the Portuguese FH Study. One of the index
patients (patient 6a) died as a result of myocardial infarction at
the start of the study, so cells were obtained from an affected
relative who carried the same variant allele (patient 6b).
RNA extraction and reverse transcriptase (RT) reaction
The blood samples were collected into ethylene diamine
tetraacetic acid (EDTA) tubes, to which an equal volume of
Lymphoprep (Axis Shield) was added. The tubes were spun in a
centrifuge for 30 min at 974 g and a temperature of 4uC to
isolate mononuclear cells (lymphocytes and monocytes). The
ring of mononuclear cells was carefully removed, resuspended in
20 ml of Hanks balanced salt solution (HBSS; Gibco; Invitrogen
Corporation), and pelleted by centrifugation for 8 min at 454 g
and 4uC. Any remaining erythrocytes were lysed by resuspen-
sion of this cell pellet in 10 ml of lysis buffer (0.01 mmol/l
TrisHCl, 0.15 mmol/l NH4Cl, pH 7.4), and incubated at 37uC
for 10–15 min, followed by centrifugation for 8 min at
1500 rpm and 4uC. The mononuclear cells were then washed
twice with HBSS by centrifugation as above. Total RNA was
extracted (RNeasy Mini Kit; Qiagen, Valencia, California, USA),
including the optional DNAse I incubation. This procedure
yielded 6.5–20 mg of total RNA (200–600 ng/ml).
To prepare cDNA, 1 mg of RNA was reverse transcribed
(Ready-To-Go You-Prime First-Strand Beads Kit; Amersham
Biosciences, Amersham, Buckinghamshire, UK).
Reverse transcriptase PCR and analysis of PCR fragments
Amplification of the cDNA fragments of interest was performed
in a T3000 thermocycler (Biometra, GmbH. Niedersachsen,
Germany). All the primers were designed using PrimerSelect
V.4.05, software, incorporated in the DNAstar software
(DNAstar Inc, Madison, Wisconsin, USA) and Primer3 soft-
ware. In order to amplify large fragments, the Expand Long
Template PCR System was also used, according to the supplier’s
instructions (Roche Applied Science, Madison, Wisconsin,
USA). All PCR products were treated with ExoSAP (USB,
Cleveland, Ohio, USA, and Amersham Biosciences) and
sequenced with the PCR forward and reverse primers (as
indicated in figure legends) in an automated sequencer with 16
capillaries (3100 Genetic Analyzer; Applied Biosystems, Foster
City, California, USA).
When necessary, common genomic sequence variations and
other fragments of the LDLR gene were analysed as described
elsewhere.10
Splice-site scores and splice-site prediction
Splice-site scores were calculated with Splice-Site Score
Calculation software (http://rulai.cshl.edu/new_alt_exon_db2/
HTML/score.html).
RESULTS
Blood samples for mRNA analysis were obtained from six index
patients, whose clinical characteristics and putative LDLR
defects are shown in table 1. The clinical phenotype of these
patients is presented in supplementary table 1 (online). The
remaining four patients, with alterations c.81822ARG,
c.1060+1GRA, c.1845+1delG and c.2547+1GRA were lost to
follow-up and fresh blood samples were unobtainable, but the
pathogenicity of these variants is not in any doubt.
Our novel approach for the isolation of total RNA from fresh
blood cells allowed the set-up of RT-PCR on the same day as
blood collection (or on the following day for samples sent by
mail). Sufficient RNA could be extracted from fresh blood
mononuclear cells to perform at least 100 PCR tests. Fragments
of LDLR mRNA were amplified by RT-PCR with appropriate
primers spanning regions encoded by different exons in order to
detect splicing variants. Fragments of up to 600 bp could be
amplified readily.
Mutations that affect mRNA splicing
c.313+6 TRC, intron 3
A single base substitution of T to C at nucleotide c.313+6 at the
59 end of intron 3 was found in a heterozygous index patient
with FH who also carried a second potentially defective allele,
A410T.10 Only the 313+6 variant was found in this patient’s
hypercholesterolaemic father (fig 1A), suggesting that this was
the pathogenic variant in the father, and that it must affect
splicing. This was supported by the calculated splice-site scores:
8.1 for the normal splice site and 3.7 for the variant site. When a
fragment of LDLR mRNA encompassing the region encoded by
exons 1 to 4 was amplified from the patient’s cells by RT-PCR,
the agarose gel electrophoresis showed the amplification of
two fragments of 441 bp (normal size product) and 318 bp
(supplementary fig 1B online). The nucleotide sequence of the
total PCR product revealed a double sequence after the
nucleotides encoded by exon 2, showing both the expected
sequence and a sequence in which exon 2 was followed by exon
4 (supplementary fig 1C online), indicating the skipping of exon
3 in the mRNA from one allele (fig 1B). This alteration was not
present in a panel of 75 normolipidaemic Portuguese controls.
c.2389GRT (p.V776L) exon 16
A single base substitution of GRT at nucleotide 2389, the last
nucleotide of exon 16, was found in a heterozygous index
patient with FH and relatives with hypercholesterolaemia (III:2
and III:3, fig 2A). From the coding sequence, this variation is
predicted to result in a conservative amino acid substitution
(V776L) that would be unlikely to affect LDLR function, but the
nucleotide also lies in the splice site at the end of exon 16.
Calculation of the splice site scores showed a reduction from 7.1
for the natural site to 3.6 for the variant site, indicating that this
alteration might affect splicing. When a fragment of mRNA
encompassing the region encoding exons 15–18 was amplified
from the index patient’s cells, agarose gel electrophoresis of the
product revealed two fragments, the expected fragment of
490 bp and a smaller fragment of approximately 412 bp
(supplementary fig 2B online). Nucleotide sequencing showed
that the 412 bp fragment corresponded to a fragment lacking
exon 16 and that fragment 490 bp corresponded to the expected
fragment (supplementary fig 2C) as demonstrated in fig 2B.
This alteration was not present in a panel of 75 normo-
lipidaemic Portuguese controls.
c.135925CRG, intron 9
A single base substitution of CRG at nucleotide 135925 at the
39 end of intron 9 was found in one index patient and other
family members with hypercholesterolaemia (II:2 and III:1,
fig 3A). However, the variant was not present in a further
family member (III:3) who also had hypercholesterolaemia, and
thus this variant gene did not show full co-segregation with the
disorder (fig 3A). Nonetheless, the nucleotide substitution
reduced the calculated splice-site score from 6.8 to 4.3. In order
to detect any effect of this mutation on splicing, a fragment of
LDLR mRNA encompassing the region encoded by exons 8–10
was amplified by RT-PCR from the patient’s cells. Agarose gel
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electrophoresis revealed two fragments in the amplification
reaction: the expected fragment of 325 bp, plus a larger
fragment of approximately 410 bp (supplementary fig 3B).
The nucleotide sequence of the total PCR product revealed a
double sequence (supplementary fig 3C), with both the
expected sequence and a sequence in which the nucleotide
sequence of exon 9 was followed by the sequence of intron 9,
showing that intron 9 was retained in the 410 bp fragment
(fig 3B). This alteration was not present in a panel of 75
normolipidaemic Portuguese controls.
Potential or reported splicing variants that do not affect splicing
c.106128TRC, intron 7
A single base substitution of TR C at nucleotide 106128 at the
39 end of intron 7 was found in one index patient and several
other family members with hypercholesterolaemia (II:1–4, II6,
and III:3; fig 4A). However, the variant was not present in a
further family member (I:2) with hypercholesterolaemia
(fig 4A), and the splice-site scores did not show any significant
difference (11.7 vs 11.8). This indicated that the alteration was
unlikely to affect splicing, and this was confirmed when mRNA
from the patient’s cells was analysed. Amplification of a
fragment of LDLR mRNA encompassing the region encoded
by exons 6–9 produced a single product of the expected size
(supplementary fig 4B). A panel of 75 normolipidaemic
Portuguese controls was also screened for this alteration and it
was found in 2 of them.
c.2140+5GRA intron 14
A single base substitution of G for A at nucleotide 2140 at the 59
end of intron 14 was found in one index patient and in a family
member with hypercholesterolaemia (II:1, fig 5A). This variant
had been reported before as the cause of FH, but this was later
refuted when the variant was found to occur in normolipidae-
mic people.20 Because the splice-score software showed a
reduction from 8.1 for the natural site to 4.7 for the variant,
we investigated whether this variant might have an effect on
RNA processing in our index patient’s cells. When a fragment of
LDLR mRNA encompassing a region encoded by exons 13–15
was amplified by RT-PCR from the patient’s cells, only the
expected fragment of 359 bp was present, (supplementary fig 5B
online), confirming that this variant has no effect on splicing. A
panel of 75 normolipidaemic Portuguese controls was screened
for this alteration and it was found in 1 of them.
Table 1 Characterisation of patients in the study
Patient
Gender
LDLR gene variant
ReferenceNo Type
Age,
years* Base substitution Location
1 Index 41–44 F 313+6TRC Intron 3 Novel
c. 1291GRA (p.A410T) Exon 9 10
2 Index 33–36 M c.2389GRT (p.V776L) Exon 16 11
3 Index 73–76 F c.135925CRG Intron 9 Novel
4 Index 13–16 M [c.106128TRC] and Intron 7 11–15
[c.2177CRT (p.T705I)] Exon 15 16 17
5 Index 61–64 F c.2140+5GRA Intron 14 11 13 18–20
6a{ Index 45–48 M c.1185GRC (p.V374V) Exon 8 Novel
c.242CRG Promotor 21 22
6b Relative of 6a 5–8 F c.1185GRC (p.V374V) Exon 8 Novel
c.242CRG Promotor 21 22
*During study; {died 2007.
Figure 1 Effect of the c313+6TRC mutation on LDLR mRNA. (A)
Pedigree of index patient 1 (indicated by arrow); half-filled black
symbols, heterozygous for 313+6TRC; half-filled light grey symbols,
heterozygous for A410T. Below each symbol are generation numbers
followed by age and pre-treatment cholesterol levels (mg/dl). (B)
Diagram showing the location of primers used and the two fragments
obtained.
Figure 2 Effect of the c.2389GRT (p.V776L) mutation on LDLR mRNA.
(A) Pedigree of index patient 2 (indicated by arrow). Half-filled black
symbols, heterozygous for the V776L mutation. Below each symbol are
generation numbers followed by age and pre-treatment cholesterol levels
in mg/dl. NF, mutation not found. (B) Location of primers used and the
representation of the two fragments obtained.
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Use of a potential splicing variant (c.1185GRC (p.V374V)) in
exon 8 to characterise a promoter mutation
A single base substitution G to C at nucleotide 1185 at the
second nucleotide of the last codon of exon 8 was found in a
heterozygous index patient with FH and other relatives with
hypercholesterolaemia (II:1 and III:2, fig 6A). There was no
difference between the calculated splice-site scores for the
normal and variant alleles (6.8 vs 6.8), but as it cosegregated
with hypercholesterolaemia in this family and no other variant
was identified, it was decided to investigate whether any
abnormal splicing could be detected. Fresh blood cells from II:1
and III:2, both heterozygous for the variant, were available, as
well as cells from another relative (III:1) who did not carry this
variant allele (fig 6A). A fragment encompassing a region
encoded by exons 6–9 was amplified from mRNA from these
cells, and agarose gel electrophoresis showed that only the
expected product of 319 bp was obtained for all three family
members (supplementary fig 6B online).
To exclude the possibility that retention of intron 8 had
resulted in an abnormal mRNA that could not be amplified by
standard RT-PCR, long-range PCR was performed using the
forward primer in exon 6 and a reverse primer in intron 8, with
the patient’s cDNA and genomic DNA as templates. Because
this amplified the correct fragment of about 4.3 kb from
genomic DNA, and no amplification was seen when mRNA
was used as template, it was clear that this alteration did not
lead to the retention of intron 8 in the mRNA (supplementary
fig 6C online).
However, analysis of the nucleotide sequences of the
amplified fragments from both affected relatives revealed that
the mRNA was apparently homozygous for the common G at
position 1185 (fig 6B), indicating that the rare allele carrying the
1185C was not detectable in mRNA. This was confirmed by
analysis of other polymorphic sites in genomic DNA and
mRNA. Individual II:1 was heterozygous for several common
polymorphisms in the LDLR coding region, and analysis of
mRNA from her cells revealed that the mRNA was apparently
homozygous at all these sites, confirming that only one
allele was expressed as mRNA (supplementary fig 6E online).
III:2 was homozygous in genomic DNA at all sites tested and
thus further analysis of her mRNA provided no additional
information.
As there was no evidence for a mutation giving rise to a
premature termination codon that might lead to rapid decay of
the mRNA, it appeared that either only one allele was
transcribed in carriers of the V374V allele, or that there was a
mutation in the non-coding region on this allele that de-
stabilised the mRNA. To investigate this, the promoter region
of the LDLR was re-analysed in genomic DNA from these
affected subjects. A single nucleotide substitution of C to G at
position 242, which lies in a critical SRE sequence21 22 was
found in all the family members with the V374V alteration and
not in the one normolipaemic relative who did not carry this
alteration (fig 6A). The cosegregation pattern indicated that
both alterations are on the same allele. These results indicated
that the allele carrying the V374V variant is apparently not
transcribed in the cells due to the promoter mutation. The
alteration V374V was not found in a panel of 75 normolipi-
daemic Portuguese controls.
DISCUSSION
Confirming whether any genetic alteration is the underlying
cause of the disease in an individual is important to establish the
Figure 3 Effect of the c.135925CRG mutation on LDLR mRNA. (A)
Pedigree of index patient 3 (indicated by arrow). Half-filled black
symbols, heterozygous for c.135925CRG. Below each symbol are
generation numbers followed by age and pre-treatment cholesterol levels
in mg/dl (except when marked with *); MI, myocardial infarction; NF,
mutation not found. (B) Location of primers used and the two fragments
obtained.
Figure 4 Lack of effect of the c.106128TRC variant on LDLR mRNA
splicing. (A) Pedigree of index patient 4 (indicated by arrow). Half-filled
black and grey symbols, heterozygous fr c.106128TRC. Below each
symbol are generation numbers followed by age and pre-treatment
cholesterol levels (mg/dl) (except when marked with *). NF, variant not
found.
Figure 5 Lack of effect of the
c.2140+5GRA alteration on mRNA
splicing. (A) Pedigree of index patient 5
(indicated by arrow). Half-filled black and
grey symbols, heterozygous for
c.106128TRC. Below each symbol are
generation numbers followed by age and
pre-treatment cholesterol levels in mg/dl.
Mutation report
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correct diagnosis so that adequate treatment and genetic
screening of the family can be implemented. For this, functional
assays are necessary for many of the novel alterations found,
especially where mRNA splice sites might be involved. The
novel method presented here allows the isolation of total RNA
from fresh blood cells and the set-up of RT-PCR on the day of
the blood collection (or on the following day for samples sent by
mail), saving weeks of the extensive cell culture necessary to
obtain stable cell lines. This novel approach uses simple
methods that will enable many researchers to investigate
putative splice-site mutations rapidly and inexpensively avoid-
ing the publication of false splice-site mutations.
Our sample of six putative splice-site mutations was
successfully analysed by the described methods. Three of the
alterations were found to affect splicing and the other three did
not. Substitution of c. 313+6 TRC leads to skipping of exon 3,
and this has been shown previously to result in very low levels
of LDL receptor activity in cells.8 The substitution
c.135925CRG led to retention of intron 9; this is predicted
to result in a protein with two additional incorrect amino acid
residues after those encoded by exon 9 followed by a
termination codon. The alteration c.2389GRT (p.V776L)
results in exon skipping, leading to the in-frame deletion of
the 26 codons of exon 16 that encode the membrane-spanning
domain important for the anchoring of the receptor to the cell
membrane. Thus these three alterations can clearly be
considered as disease-causing mutations. None of the 75 people
from a control group of the Portuguese normolipidaemic
population had these alterations.
Two of the variants tested did not affect splicing. One of
these, c.106128TRC, did not cosegregate with hypercholesterol-
aemia in the family, thus raising doubts about its pathogeni-
city, and furthermore, it was located in the last nucleotide of
the consensus splice-site sequence, considered to be relatively
unimportant for correct splicing. As described previously,11–15
the c.106128TRC splice-site alteration is most likely a
paucimorphism in complete linkage disequilibrium with the
T705I mutation, and indeed this same alteration, now
considered to be non-pathogenic,16 17 was also present in our
index patient. As described previously,15 this modification in
the polypyrimidine tract of the splice-acceptor site for intron
7 is not predicted to have a significant effect on splicing, as
was shown in our study. In our population this alteration
seems to be a polymorphism. as it was found in 2 of 75
normolipidaemic Portuguese controls.
The second alteration that had no effect on splicing, c.2140+5
GRA, has been described previously as the cause of disease in
other patients with FH, but has also been reported to occur in
normolipidaemic subjects,20 thus our result was not surprising.
In addition, the analysis of 75 Portuguese normolipidaemic
controls revealed that 1 had this common alteration, indicating
that this is a polymorphism as it is present in .1% of a normal
population. It is worth noting that the SSSC software predicted
a marked decrease in the splice-site score for this variant allele,
and therefore failed to predict the correct effect of this alteration
on mRNA splicing. Another commonly used algorithm for the
prediction of splice mutations (SSPNN)23 gave similar results,
although the numerical values were different (supplementary
table 2 online), and if anything, the score for the variant was
relatively lower according to SSPNN. This indicates that
software can only be used to suggest possible splice variants,
and that functional characterisation is always necessary for
confirmation. Although no variant products were detected, and
this variant occurs in normolipidaemic people, it is possible that
splicing is less efficient for this allele, which could be determined
by quantitative RT-PCR. However, little is known about
whether both alleles are expressed equally in normolipidaemic
individuals, so this question is outside the scope of this paper
but is currently under investigation.
Some reports describe distinct splicing patterns in different
cell types, and some variant splicing has been found for exons 4
and 12 of the LDL receptor gene in normolipidaemic people.24 25
In our study, we compared LDLR mRNA splicing in the same
cells (fresh lymphocytes) from normolipidaemic and hyperch-
olesterolaemic individuals, suggesting that the different splicing
patterns we found are most probably the cause of their disease.
None of our mutations involved exons 4 or 12. Ideally, LDL
receptor mRNA splicing should be assessed in the patient’s
hepatocytes, but this is clearly not feasible.
Any effect of the V374V alteration on splicing could not be
assessed, as it was located on an allele that also has a mutation
at position 242 in the proximal promoter of LDLR. This
mutation apparently lead to the non-production of mRNA, as
determined from a comparison of common sequence variations
Figure 6 Analysis of LDLR mRNA in
cells from carriers of c.1185GRC
(V374V) and 242GRC. A) Pedigree of
index patient 6 (indicated by arrow). Half-
filled black symbols, heterozygous for the
c.1185GRC and 242GRC; crossed
symbol, index patient is deceased. Below
each symbol are generation numbers
followed by age and pre-treatment
cholesterol levels (mg/dl). MI, myocardial
infarction; NF, where the family mutation
was not found. (B) Nucleotide sequences
of a fragment containing exon 8 and
intron 8 amplified from genomic DNA,
showing heterozygosity for c.1185GRC
in both relatives II:1 and III:2, and of a
fragment of LDLR mRNA encompassing
exons 6–9 amplified by RT-PCR from the
patient’s cells, showing homozygosity for
the common allele.
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in mRNA and DNA from one of the affected patients who was
heterozygous at several sites in the genomic DNA, as well as
from the absence of the V374 variant in mRNA from all carriers.
This promoter mutation has been described previously21 22 but
no cell studies had been carried out to confirm its effect. Other
promoter mutations in the same SRE (eg, at 243 and 24926 27)
have been reported to reduce mRNA expression.
There is little doubt about their pathogenicity of the
remaining putative splice-site alterations that were not studied
here at the mRNA level (c.81822ARG, c.1060+1GRA,
c.1845+1delG and c.2547+1GRA). Three of these affect the G
in the GT at the 59 end of an intron, the most conserved region
for splicing. A mutation in this location (c.313+1 GRA that has
previously been shown to affect splicing8 was also found in the
Portuguese FH study.9 The fourth variant changes the invariant
AG in the acceptor splice site for intron 8 to GG, and similar
mutations at the equivalent site in other introns of the LDLR
have been confirmed to result in mis-splicing.26 28
Even though all the patients analysed in this study presented
with a clinical diagnosis of possible FH9 with very high levels of
total cholesterol (.290 mg/dl), not all the rare putative splice
variants found in these patients are the cause of their disease,
and other causes must now be sought. It is possible that
patients with no functional mutation in LDLR have other
variants more distant from intron:exon junctions that affect
splicing by influencing cis elements, such as splicing enhancers,
exonic and intronic splicing enhancers or splicing silencers, and
exonic and intronic splicing silencers, which usually interact
with splicing stimulator or inhibitor factors.29–31 None of these
has yet been described in the LDL receptor gene.
Our findings emphasise the care that must be taken before
reporting the presence or absence of a splice-site mutation in the
LDLR gene for diagnostic purposes. Our study also encourages
the implementation of RNA studies to evaluate putative
splicing mutations, which in some cases, are not predicted by
the available software and could lead to patients being
misdiagnosed on a genetic basis.
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